TuHURA Biosciences, Inc./NV

HURA · Nasdaq · SIC 2834: Pharmaceutical Preparations
331
SEC Filings

Business Summary

Overview We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to trick the bodys immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designe...

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionHURAdiscussed_in_filing Cybersecurity
topic_mentionHURAdiscussed_in_filing Cybersecurity
topic_mentionHURAdiscussed_in_filing Healthcare & Bio
topic_mentionHURAdiscussed_in_filing Platform & Ecosystem
topic_mentionHURAdiscussed_in_filing Healthcare & Bio
topic_mentionHURAdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134950EDGAR90K words
2025-03-312024-12-310000950170-25-047921EDGAR—
2024-10-072024-06-300000950170-24-113321EDGAR—
2023-09-182023-06-300000950170-23-048588EDGAR—
2022-09-272022-06-300000950170-22-018865EDGAR—
2021-09-282021-06-300001564590-21-049235EDGAR—
2020-09-182020-06-300001564590-20-044019EDGAR—
2019-09-092019-06-300001213900-19-017497EDGAR—
2018-09-242018-06-300001213900-18-012876EDGAR—
2017-09-272017-06-300001213900-17-010055EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-281539EDGAR26K words
2025-08-142025-06-300000950170-25-108972EDGAR—
2025-05-152025-03-310000950170-25-072745EDGAR—
2024-11-142024-09-300000950170-24-127199EDGAR—
2024-05-142024-03-310000950170-24-059694EDGAR—
2024-02-142023-12-310000950170-24-015204EDGAR—
2023-11-132023-09-300000950170-23-062915EDGAR—
2023-05-112023-03-310000950170-23-020854EDGAR—
2023-02-142022-12-310000950170-23-002805EDGAR—
2022-11-092022-09-300000950170-22-023988EDGAR—
2022-05-132022-03-310000950170-22-009809EDGAR—
2022-02-112021-12-310001564590-22-004688EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-010001193125-26-135766EDGAR1K words
2026-01-300001193125-26-031742EDGAR—
2025-12-100001193125-25-314302EDGAR—
2025-12-050001193125-25-309853EDGAR—
2025-11-250001193125-25-294581EDGAR—
2025-11-180001193125-25-286419EDGAR—
2025-11-140001193125-25-281522EDGAR—
2025-11-040001193125-25-263523EDGAR—
2025-11-030001193125-25-262562EDGAR—
2025-10-310001193125-25-260924EDGAR—

331 total filings indexed. 299 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001498382
TickerHURA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedNV

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: ad876a09fa473c3b8232cdb8675fe558375d3a6ab17ed1a7c8dfb90d94d7c669
parent: 160591f351a1b8fb3c9ecd96432302cebc9b9c6e25e6fadf619caf68079ffdc0
content hash: 4864942ba371877cea0036c1ef29a85a60a3dfc92d359fb467848215bd027800
signed: 2026-04-13T04:45:34.598Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf